MB Rahastot invests in Pharmatory to support its growth and expansion into the HPAPI market.

Target Information

MB Rahastot has made a strategic investment in Pharmatory, a Finnish contract development and manufacturing organization (CDMO) specializing in the development and production of small-molecule active pharmaceutical ingredients (APIs). This partnership aims to support Pharmatory's growth and expansion. The existing management team will continue to lead the company in their current roles and remain significant shareholders alongside MB Rahastot.

Founded in 2001, Pharmatory provides services to international pharmaceutical and biotechnology companies, acting as a contract development and manufacturing partner for both human and veterinary medicines. Their offerings include analytical services, process development, and contract manufacturing, all in compliance with Good Manufacturing Practices (GMP) certification. Pharmatory prides itself on developing long-term customer partnerships and operates a state-of-the-art facility in Oulu, staffed by a team of experienced professionals with extensive expertise in the chemical sector.

Industry Overview

In Finland, the pharmaceutical industry is a critical sector characterized by its dynamic environment and strong growth potential. The country has a robust framework for biopharmaceutical research and development, bolstered by its commitment